http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007105929-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c26c0ec3a2485dac1e938e39b3672696 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_749a3e0d44c034e41dae95cd5e49ae68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_404a0ff0e13d26e869ef2adb7b7ce673 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-205 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138 |
| filingDate | 2006-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_581b52837823fd358295a3dc8c6d451a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8082d679c10e0b1bdc4a923bd430370a |
| publicationDate | 2007-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2007105929-A1 |
| titleOfInvention | Synergistic pharmaceutical composition of tramadol and lysine clonixinate |
| abstract | The present invention relates to pharmaceutical compositions that contain two active principles, one being a known opiate analgesic, such as tramadol or one of the enantiomers thereof or one of the pharmaceutically acceptable salts thereof, and the other a non-steroidal anti-inflammatory analgesic known as lysine clonixinate. When the two drugs are combined in specific proportions, the combination produces pharmacological effects of analgesia, indicating super-additivity (synergy), and it is therefore possible to use a smaller quantity of both drugs to achieve the same level of analgesia than when they are used alone. When the amount of each drug in the combination is reduced, the side effects associated with each of them are reduced in number and in severity, and therefore this therapeutic strategy may constitute a promising tool in the relief of moderate to severe acute pain, with the advantage that there are fewer adverse effects typical of opioids, such as a predisposition to abuse, tolerance, constipation and respiratory depression. |
| priorityDate | 2006-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 79.